RVMD FY 2019 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+148.2% YoY

Gross Profit

$50M100.0% margin

Operating Income

-$54M-108.2% margin

Net Income

-$48M-95.2% margin

EPS (Diluted)

$-1.31

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$52M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$221M

Total Liabilities

$68M

Stockholders' Equity

$153M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$20M	+148.2%
Gross Profit	$50M	$20M	+148.2%
Operating Income	-$54M	-$40M	-34.2%
Net Income	-$48M	-$42M	-14.1%